NPS Pharmaceuticals | Evaluate

February 16, 2016

Zealand plays catch-up with Shire in short bowel syndrome

Shire shines as a post-AbbVie solo act

January 15, 2015

Mega-merger drought fails to impede record-breaking acquisition year

January 12, 2015

Natpara risk overshadows Shire’s NPS takeout

November 04, 2014

PD-1s make way for the next wave of blockbuster launches

October 16, 2014

Shabbvie is dead; long live Shire

October 10, 2014

Upcoming events: Rett data for Neuren while NPS awaits Natpara approval

September 22, 2014

Still unpartnered, but now worth a lot more

August 29, 2014

Upcoming events: FDA panels take on liraglutide and Natpara

July 22, 2014

Small-molecule launches hold their own

February 19, 2014

Vantage Point – Four-tier drug plans thrust affordability into spotlight

Load More